Pages

Friday, April 10, 2015

健亞+國衛院+中奇製藥/石家莊) CFDA同意進行臨床試驗 (DBPR108)

(

健亞:本公司治療新陳代謝異常之新成份新藥DBPR108經中國大陸國家食品藥品監督管理總局核發藥物臨床試驗批件,同意進行臨床試驗。 鉅亨網新聞中心2015-04-09 16:10:37第二條第511.事實發生日:104/04/09 2.公司名稱:健亞生物科技股份有限公司3.與公司關係[請輸入本公司或子公司]:本公司4.相互持股比例:不適用5.傳播媒體名稱:不適用6.報導內容:不適用7.發生緣由:.研發新藥名稱或代號:DBPR108.用途:治療新陳代謝異常(但尚未證明有療效)。三.預計進行之所有研發階段:第一期臨床試驗,第二期臨床試驗,第三期臨床試驗及新藥上市申請。四.目前進行中之研發階段:1.本公司於10112月間,與中國大陸石藥集團中奇製藥技術(石家莊)有限公司,就DBPR108在中國大陸地區共同進行該藥品之研究,註冊,推廣,銷售和生產等事宜,簽署技術授權與開發合同2.中奇製藥日前接獲中國大陸國家食品葯品監督管理總局核發藥物臨床試驗批件,同意DBPR108臨床試驗之進行。3.已投入之累積研發費用:不適用(中國大陸臨床開發費用由中奇製葯全權負責)。五.將再進行之下一研發階段:第二期臨床試驗,第三期臨床試驗及新藥上市申請。1.預計完成時間:本試驗相關時程之規劃,由中奇製葯主導。2.預計應負擔之義務:與國衛院共同協助中奇製葯之臨床開發工作8.因應措施:9.其他應敘明事項:新藥開發時程長,投入經費高且並未保證一定能成功,此等可能使投資面臨風險。投資人應審慎判斷謹慎投資。

 

(NATURE) “廣效”抗體(3BNC117 ) 治療/預防 愛滋病(一年一劑) !!

Antibody shows promise as treatment for HIV Clinical trial is encouraging first step to developing new approach to HIV prevention, treatment and cure. 08 April 2015  Antibody treatment reduced levels of HIV in study participants for 28 days. Treating HIV with an antibody can reduce the levels of the virus in people's bodies — at least temporarily, scientists report on 8 April in Nature1.The approach, called passive immunization, involves infusing antibodies into a person's blood. Several trials are under way in humans, and researchers hope that the approach could help to prevent, treat or even cure HIV. The work is a milestone towards those goals, says Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland. "This is an early study, but it's a study with some impressive results," he says. Researchers tested four different doses of an HIV antibody called 3BNC117 in 29 people in the United States and Germany. Seventeen of the participants had HIV, and 15 of those were not taking antiretroviral (ARV) drugs at the time of the study. One infusion of the highest dose of antibody, given to 8 participants, cut the amount of virus in their blood by between 8 and 250 times for 28 days. Previous studies have shown that passive immunization can reduce levels of HIV in the blood of monkeys and mice, although the approach has not worked as well in humans2. But the antibodies used in those earlier clinical tests were of an older generation that could not neutralize many different strains of HIV. Researchers have spent much of the past decade trying to find 'broadly neutralizing' antibodies that are more widely effective against the virus, and the 3BNC117 antibody belongs to this class. The price of treatment with this approach is also a concern. Antibodies can cost thousands of dollars for each course of treatment, and the majority of people with HIV are in low- and middle-income countries, some of which are already fighting drug companies over the high cost of antibody medicines. "The practicality, utility and efficacy of this approach are hugely open questions," says Mitchell Warren, executive director of AVAC, a global organization that advocates HIV prevention and is headquartered in New York City. Even with improved antibodies, researchers still face a vexing problem: HIV mutates quickly as it replicates in the human body, which can reduce the effectiveness of treatments over time. The study's authors found that this was true for the single antibody that they tested. In two people who received the highest dose of 3BNC117, the antibody became roughly 80% less effective at neutralizing HIV after 28 days of treatment — probably because the virus changed shape to evade the antibody. As a result, it is unlikely that a single antibody alone could treat people who have HIV, says the study's lead author, Michel Nussenzweig, an infectious-disease physician and immunologist at the Rockefeller University in New York. Instead, therapies would use combinations of antibodies. Nussenzweig's group has produced a second HIV antibody and hopes to test it alone and in combination with 3BNC117 this year."The goal is a once-a-year shot for prevention and a combination approach for cure," he says, adding that this immunotherapy approach to treating HIV would resemble treatments now used against cancer.Relying on combinations of antibodies would raise the costs of passive-immunization treatments for HIV. But Warren says that this is not necessarily a deal-breaker, noting that patient advocacy and concessions by drug companies have helped to reduce the high cost of ARV medications over the past two decades. "Some people would have said 10–15 years ago that ARVs were not going to be affordable, either," he adds. Nature doi:10.1038/nature.2015.17260

河北 成為 阿里健康云 医院/藥局 o2o平台 !!!

河北健康服务产业将插上"互联网+"翅膀41日,在石家庄市高新区工商局,阿里健康河北信息技术有限公司业务总监黄建良从工作人员手中接过营业执照,这意味着阿里健康区域总部正式落户石家庄。阿里健康区域总部负责北方省份的健康服务产业相关业务,将围绕健康服务产业链,帮助河北省企业投资健康信息化领域,扶持发展一批高水平的研发、设计企业,支持河北省企业加大力度发展创新医疗产品,如可穿戴设备、健康监测设备等。同时利用大数据,引导河北省企业开发适合市场需求的健康产品,并通过阿里健康平台辐射全国。阿里健康是阿里巴巴集团附属公司,其目标是打造"整合医疗全体系、全链条资源,提供全方位医疗服务的互联网平台"。业内专家分析,与互联网密切结合,将为健康服务产业带来全新机遇和广阔发展空间。随着阿里健康区域总部入驻,河北健康服务产业也将插上"互联网+"翅膀。阿里健康区域总部落户河北并非偶然。去年6月,河北省与阿里巴巴集团签署战略合作框架协议。根据协议,阿里巴巴将在河北布"云",建设一个基于云计算、大数据与数字互联网的"智慧河北"。阿里巴巴集团董事局主席马云表示,作为集团重大决策,阿里巴巴将把网上药品销售平台放在河北。随着阿里健康区域总部在河北布局,河北省与阿里巴巴集团的合作也向纵深拓展。去年11月,石家庄在全国率先上线基于拍照模式的阿里健康手机客户端,市民"尝鲜"了医院看病药店买药。今年3月,河北省胸科医院又在全国范围内首次实现涵盖多科室的电子处方规模化流转,该院患者向社会药店买药更方便。与此同时,石家庄市平衡体检中心接入阿里健康云医院平台,通过客户端,患者能够直接与云医院的数万名医疗专家开展互动问诊。

阿裡健康總部石家莊(河北) 強化 穿戴醫療/健康監測設備

阿里健康区域总部落户石家庄 2015040915:17中国电子商务研究中心(中国电子商务研究中心讯)41日,在石家庄市高新区工商局,阿里健康河北信息技术有限公司业务总监黄建良从工作人员手中接过营业执照,这意味着阿里健康区域总部正式落户石家庄。阿里健康区域总部负责北方省份的健康服务产业相关业务,将围绕健康服务产业链,帮助我省企业投资健康信息化领域,扶持发展一批高水平的研发、设计企业,支持我省企业加大力度发展创新医疗产品,如可穿戴设备、健康监测设备等。同时利用大数据,引导我省企业开发适合市场需求的健康产品,并通过阿里健康平台辐射全国。阿里健康是阿里巴巴集团附属公司,其目标是打造"整合医疗全体系、全链条资源,提供全方位医疗服务的互联网平台"。业内专家分析,与互联网密切结合,将为健康服务产业带来全新机遇和广阔发展空间。随着阿里健康区域总部入驻,河北健康服务产业也将插上"互联网+"翅膀。阿里健康区域总部落户河北并非偶然。去年6月,我省与阿里巴巴集团签署战略合作框架协议。根据协议,阿里巴巴将在河北布"云",建设一个基于云计算、大数据与数字互联网的"智慧河北"。阿里巴巴集团董事局主席马云表示,作为集团重大决策,阿里巴巴将把网上药品销售平台放在河北。随着阿里健康区域总部在河北布局,我省与阿里巴巴集团的合作也向纵深拓展。去年11月,石家庄在全国率先上线基于拍照模式的阿里健康手机客户端,市民"尝鲜"了医院看病药店买药。今年3月,河北省胸科医院又在全国范围内首次实现涵盖多科室的电子处方规模化流转,该院患者向社会药店买药更方便。与此同时,石家庄市平衡体检中心接入阿里健康云医院平台,通过客户端,患者能够直接与云医院的数万名医疗专家开展互动问诊。(来源:河北日报)

安成 新總經理: 陳貞如 / 陳志光 轉 顧問!!

安成藥CEO 陳貞如接任 2015-03-06 04:57:11 經濟日報 記者高行/台北報導安成藥業(4180)董事會昨(5)日決議,由原任旗下美國子公司總經理陳貞如接任執行長兼總經理,原總經理陳志光將轉任執行長特別顧問,仍任子公司安成生技總經理。該項人事改組主要基於產品即將進入上市階段的考量。安成藥業指出,旗下產品即將進入商業量產及上市銷售,盼借重陳貞如曾在全球最大學名藥公司Teva擔任事業開發副總的實戰經驗,率領團隊進軍全球最大藥品消費市場的美國,躋身世界一流特殊學名藥廠之列。後續職掌安成兵符的陳貞如,在特殊學名藥、品牌藥及生物類似藥等領域極為嫻熟,對美洲區域學名藥及品牌藥物事業購併、合資合作、企業分割、技術及產品之對內及對外授權等經驗豐富,總計在美洲地累積逾18年實務經驗。除接任執行長兼總經理,陳貞如仍續任安成美國子公司總經理,此項人事案預計41日生效。同時間,安成也聘任何一華擔任財務長,9日履新。新任財務長何一華擁有美國會計師執照,先前在宏碁及特力集團擔任財務長多年,並曾在昇陽、甲骨文等知名科技業服務,策略及財務規劃經驗豐富。

 

紅電醫營收2.25億元 年增率124% (2014)

紅電醫 去年營收倍增 2015-04-09 經濟日報 蔡穎青 群益金鼎證券今(9)日在該公司13樓,舉辦紅電醫學科技(1799)法人說明會,歡迎法人、投資人出席參與。群益金鼎證券指出,紅電醫2014年度合併營收近2.25億元,較前年度成長超過一倍,年增率達124%,而2015年前兩個月累計合併營收年增率達440%,預期三月份業績表現依然亮麗。紅電醫自華威國際科技合夥人李世仁博士於2013年擔任董事長以來,持續強化競爭力,積極調整產品組合及新增客戶,除開發醫療器材新品項貢獻業績陸續發酵,該公司並於2014年第三季跨入藥物銷售及研發領域。在原有醫材產業基礎下,經營團隊整合國內外經驗與資源,挑戰新劑型藥物開發事業,目標市場鎖定美國。該公司預計今年度將有產品向美國食品藥品管理局 (FDA)申請認證,經營團隊有信心,在藥物開發方面,將陸續開花結果。紅電醫自去年第四季以來,來自原料藥的營業額已明顯超越體溫量測產品。藥物研發將進入申請認證階段,未來更增添營運成長動能與競爭利基。

紅電醫 動力主軸: 藥: Rx-to-OTC/505 b2/ 醫材: 藍芽婦女基礎體溫計/幼兒發燒監測

藥物、醫材雙引擎 紅電醫轉機浮現 2015-04-0920:54 〔記者陳永吉/台北報導〕經過華威國際掌握紅電醫(1799)經營權後,這一年多來的體質調整,今天正式舉行法說會,紅電醫董事長李世仁表示,紅電醫現在不論在技術、產品及財務結構上,都已經大幅蛻變,最重要是找到對的人進公司,未來將打造紅電醫為世界級的生醫公司。 李世仁指出,現在紅電醫的事業群,除了原有的醫材外,也新增藥物事業群。目前藥物事業群鎖定Rx-to-OTC藥物及新劑型(505b)(2))藥物市場,其中Rx-to-OTC藥物指的是處方藥專利到期後,原廠選擇到不須處方的OTC或藥房等通路銷售,由於藥物安全性高,加上取得方便,轉成Rx-to-OTC藥物後,市場還會擴大,常見的如治療咳嗽、發燒、止痛、過敏、腸胃藥等,現在紅電醫也鎖定4Rx-to-OTC藥物進行開發。 其中進度最快的為咳嗽藥,今年就能完成臨床試驗申請美國藥證,不過公司表示,從申請藥證到核准,至少需要一年以上時間,另外3項產品預期2016年可申請藥證。 此外紅電醫也在開發2項中樞神經疾病(505b)(2))新藥,並將與現在的策略夥伴輝瑞等藥廠洽談合作,整合其資源以加快藥品上市。 至於過去的主力產品—醫材,除了以往經營的高階產品外,也會往中低階市場開發,另外也開發功能型體溫計,如具藍芽功能的婦女基礎體溫計、幼兒發燒監測產品等 紅電醫去年營收年增率達124%,今年首季營收年增率也高達401%,公司希望開發中的藥物2年後陸續取得藥證開始銷售後,對營運將有大幅度的貢獻。

展旺 顧曼芹 籌資3.5億擴廠 !

展旺籌資3.5億元償還擴廠資金 今富族網記者吳泓駿/報導 2015-04-08 展旺(4167)積極投入擴廠計畫,分別於南科及竹科擴建新廠,其中南科二廠已於去年第二季完工,但由於取得藥證仍需時間,產能仍無法擴大,因此透過向銀行借款,以支應購料及購買機器設備所需資金,然而為避免利息支出費用侵蝕獲利,公司規劃籌資3.5億元,主要用於償還銀行借貸。 展旺申報辦理1.4億元現金增資於今(8)日生效,發行價格暫定以25元發行,預計可募得3.5億元資金,待5月募集完成之後,即可於今年第二季及第三季償還銀行借款。展旺近年利息費用持續攀升,2012年至2014年利息費用占稅前淨損的比率,分別為4.83%9.46%10.22%,對公司獲利造成影響,透過增資可望降低負債比,改善整體財務結構。 展旺主要從事原料藥產品的生產及銷售,目前核心商品為廣效型抗生素美洛培南(Meropenem)及亞胺培南/西司他丁(Imipenem/Cilastatin),市場以外銷為主,約佔九成以上,銷售地區遍及歐洲、中東、美洲及亞洲等地,生產基地位於竹南科學園區及台南科學園區,竹南廠生產Meropenem已獲利多年,南科一廠Imipenem/Cilastatin也已開始量產。 因應營運規模成長所需,公司啟動擴廠計畫,相繼於南科及竹科擴建新廠,竹南二廠預計今年第二季完工;而南科二廠雖已完工,但目前MeropenemErtapenem仍在查驗登記階段,產品無法出貨至歐美,不過近日就會取得台灣GMP查廠核准文件,即可立即出貨Meropenem至非法規國家。至於Ertapenem的專利將在2017年底到期,公司目前向美國與台灣提出針劑的藥證申請,力拼在2017年專利到期之前上市。

Mylan,收購Perrigo (300億美元)

289億美元 Mylan將併愛爾蘭製藥商 2015-04-10 03:58:17 經濟日報 編譯林佳賢/綜合 外電全球併購活動持續熱絡,學名藥廠Mylan正提議以將近300億美元,收購愛爾蘭製藥商Perrigo若按當前步調,今年全球全年併購規模可望超越3.7兆美元,寫下史上第二高紀錄。Mylan公司8日提議以每股205美元的股票和現金、總額289億美元,收購Perrigo,出價比Perrigo7日收盤價溢價25%生產肌膚凝膠和注射劑等產品的Perrigo表示,將召開董事會討論收購提議,還不確定是否接受。這兩家公司雖非家喻戶曉的藥廠,但合併後將創造出年營收153益美元的全球最大平價藥品販售商。Mylan股價9日盤中跌0.7%67.9美元,Perrigo股價則漲0.3%195.66美元。生產約1,400種藥品的Mylan,去年曾斥資53億美元收購亞培的非美國事業,作為搬遷納稅地址計畫的一環。但這次提議收購Perrigo,是Mylan嘗試過規模最大的收購案Perrigo 2013年也透過收購愛爾蘭的愛蘭藥廠(Elan)完成稅籍轉移,但目前兩家公司的營運總部仍都在美國。隨著企業對經濟愈來愈有信心,開始動用手上的龐大現金追求未來成長。Dealogic公司的資料顯示,Mylan出價289億美元收購Perrigo,使今年來全球企業宣布的併購總金額突破1兆美元。若按照目前步調,全球企業今年全年併購金額將突破3.7兆美元,成為2007年以外併購活動最熱絡的一年。荷蘭皇家殼牌日前宣布以約700億美元收購英國天然氣集團(BG Group),為石油與天然氣產業至少十年來最大交易案。Dealogic指出,今年來提議或宣佈收購的企業中,有15家市值超過100億美元,創下該公司數據的最高紀錄。

 

陳景虹 主持 南加大「蔡明忠轉譯醫學研究實驗室」

中研院士施陳景虹開發新藥有效抑制腫瘤 發稿時間:2015/04/10 07:38 最新更新:2015/04/10 10:39 (中央社記者吳協昌洛杉磯9日專電)南加州大學藥學院教授,同時也是中央研究院院士的施陳景虹帶領的團隊,創造出新的「共軛」分子,能抑制小鼠的前列腺癌,也獲選為美國化學學會期刊的封面文章。目前在南加大藥學院任教的施陳景虹是腦神經化學家,以對人類腦神經的研究而聞名,對於MAO-A的研究已有30年,也被尊稱為「MAO基因研究之母」。這次能夠找出方法,有效抑制腫廇,對於醫學上是一大突破。施陳景虹與其團隊將抗抑鬱藥加染料,完成不可能的配對,創造出結合兩個單獨分子的「共軛」分子NMI,產生腫廇靶向性的工具。研究結果顯示,NMI分子結合標靶癌細胞的近紅外染料以及常用的抗抑鬱藥MAO-A(單胺氧化酶A)抑制劑,能有效的減少、甚至消除小鼠前列腺腫瘤的生長。施陳景虹說,對於這個MAO-A共軛分子的染料,專門針對癌細胞,比任何已知的MAO-A本身更有效,希望可以用於治療前列腺與其他癌症。同樣參與這項研究的南加大藥理學教授歐連育克(Bogdan Olenyuk)也強調,初步結果令人鼓舞,這也是南加大台灣轉譯醫學研究中心團隊合作下的代表作,未來將在這個基礎上,開發更有效的疾病治療1040410

Rationale for Phase 2 Trial of Phenelzine (a Monoamine Oxidase Inhibitor) for Nonmetastatic Recurrent Prostate Cancer

Background: Monoamine oxidase A (MAOA) is an androgen regulated gene [1] which is highly expressed in the basal cell layer of normal prostate glands [2] and in high grade prostate cancer [3]. Clorgyline, an irreversible MAOA inhibitor, decreases expression of PSA and other androgenresponsive target genes and decreases prostate cancer cell growth in vitro [2, 4]. More recently, MAOA has been shown to exert effects on prostate tumor formation and metastasis through epithelial-mesenchymal transition and angiogenesis [5]. Importantly, MAOA expression was associated with worse outcomes in prostate cancer patients and pharmacologic inhibition of MAOA activity was associated with decreased tumor growth in prostate cancer xenograft models [5]. Thus, we have initiated a clinical trial to explore potential anti-cancer effects of phenelzine (Nardil, an irreversible MAOA/B inhibitor) in patients with recurrent prostate cancer. Methods: A non-randomized phase II trial will explore efficacy of phenelzine 30 mg orally twice daily in 46 subjects (23 in each group with non-castrate or castrate circulating androgen levels). Main eligibility criteria include: recurrent prostate cancer defined by PSA ≥ 0.4 ng/ml (post-prostatectomy) or PSA ≥ 2 ng/ml above a post-therapy nadir (postradiation therapy or primary androgen deprivation therapy). No evidence of metastatic cancer on imaging studies. No history of mania or concurrent use of food or medicines with potential interactions with MAO inhibitors. Patients may have castrate or non-castrate circulating androgen levels but no androgen-directed therapies may be initiated during the study treatment. Primary endpoint: To assess the proportion of patients who achieve a PSA decline of ≥50% from baseline. Statistical methodology: A Simon minimax two-stage design will be used to test the hypothesis that probability of response to phenelzine (P1) is ≥20% and reject the drug if the response probability (P0) is ≤ 5% for each group of patients [3]. An interim analysis will be undertaken when 12 patients have been treated with phenelzine and are evaluable for a PSA response. With this design there is 0.8 probability (power) that we will conclude that phenelzine warrants further study when the true response rate is 20% or greater, and there is only a 0.08 probability (alpha) that we will conclude that this regimen warrants further study when the response rate is 5% or less. The trial is currently active and seeking to enroll 23 subjects into each group to obtain at least 21 evaluable patients.

ClinicalTrials.gov Identifier: NCT02217709

Funding: USC- Taiwan Center for Translational Research supported by Tsai Family Fund to Jean C. Shih

1. Ou, X.M., K. Chen, and J.C. Shih, Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem, 2006. 281(30): p. 21512-25.

2. Zhao, H., et al., Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation, 2008. 76(7): p. 820-30.

3. True, L., et al., A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A, 2006. 103(29): p. 10991-6.

4. Flamand, V., H. Zhao, and D.M. Peehl, Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol, 2010. 136(11): p. 1761-71.

5. Wu, J.B., et al., Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest, 2014. 124(7): p. 2891-908.

Center for USC-Taiwan Translational Research  The Center for USC-Taiwan Translational Research focuses on promising new work in the fight against cancer. USC Trustee Daniel M. Tsai made a gift to the USC School of Pharmacy to establish the USC Daniel Tsai Fund for Translational Research which supports center activities. Currently, center scientists are exploring new cancer therapies that target monoamine oxidase (MAO). Dr. Jean Chen Shih, internationally known for her decades-long, foundational exploration on MAO, directs the center. Central to the activities of the center are the awarding of fellowships to promising graduate students and postdoctoral trainees from Taiwan and USC to allow them to work together side-by-side on translational research endeavors. These "Tsai Scholars" will spend one to two years in USC School of Pharmacy laboratories, learning cutting-edge techniques as they work on novel research programs that aim to develop the next generation of therapeutics. Tsai Scholars will be integral members of these translational research teams. These teams are investigating the use of MAO inhibitors in the treatment of cancer. Recent work from the lab of Dr. Shih has shown that elimination of the gene that encodes monoamine oxidase (MAO) prevents the growth of prostate cancer in mice. As MAO is an important regulator of mood and motivation in the brain, there are already a number of drugs that effectively inhibit its function, called MAOI (MAO inhibitors), which are used clinically as antidepressants. Given the urgent and unmet need for more effective target-based therapies to significantly reduce the lethal outcome of prostate cancer, the repurposing of these drugs may represent a rapid and cost-effective solution. This presents an extraordinary opportunity to translate scientific discovery to patient therapies on an accelerated timeframe. Dr. Shih, a University Professor and the Boyd P. and Elsie D. Welin Professor in Pharmaceutical Sciences, is a globally recognized expert on the MAO genes. Her expertise will be complemented by a group of colleague scientists from USC and in Taiwan. The center will provide a unique international collaboration for students and their mentors.

保瑞藥 解競業限制 (盛保熙/沈尚弘/何小台/陳世民/李勝文/楊朝旭/林瑞益)

保瑞藥業:公告本公司104年第二次股東臨時會決議解除新任董事及其代表人及其指派代表人之競業限制 鉅亨網新聞中心2015-04-09 20:56:31第三十四條第221.股東會決議日:104/04/09 2.許可從事競業行為之董事姓名及職稱:董事:盛保熙、大亞創業投資股份有限公司及其代表人沈尚弘、啟航貳創業投資股份有限公司及其代表人何小台、陳世民獨立董事:李勝文、楊朝旭、林瑞益3.許可從事競業行為之項目:與本公司營業範圍相同或類似之公司。4.許可從事競業行為之期間:任職本公司董事職務期間。5.決議情形(請依公司法第209條說明表決結果):經主席徵詢全體出席股東無異議照案通過。6.所許可之競業行為如屬大陸地區事業之營業者,董事姓名及職稱(非屬大陸地區事業之營業者,以下欄位請輸不適用):不適用。7.所擔任該大陸地區事業之公司名稱及職務:不適用。8.所擔任該大陸地區事業地址:不適用。9.所擔任該大陸地區事業營業項目:不適用。10.對本公司財務業務之影響程度:不適用。11.董事如有對該大陸地區事業從事投資者,其投資金額及持股比例:不適用。12.其他應敘明事項:無。

 

 

保瑞藥 監察人:李欣&賴欣儀 /董事: 陳冠百!!

保瑞藥業:公告本公司104年第二次股東臨時會全面改選監察人當選名單 鉅亨網新聞中心2015-04-09 19:52:50第三十四條第61.發生變動日期:104/04/09 2.舊任者姓名及簡歷:宏誠創業投資股份有限公司及其代表人賴欣儀,本公司監察人。英屬維京群島商CENTRAL CHIEF LIMITED及其代表人:李欣,本公司監察人3.新任者姓名及簡歷:宏誠創業投資股份有限公司及其代表人賴欣儀,本公司監察人。李欣,本公司法人監察人之代表人。百川國際投資股份有限公司及其代表人陳冠百,本公司董事。4.異動情形(請輸入「辭職」、「解任」、「任期屆滿」或「新任」):解任及新任。5.異動原因:為落實公司治理及符合相關法令之規定,本公司全面改選董事及監察人。6.新任監察人選任時持股數:宏誠創業投資股份有限公司:1,700,000股。李欣:0股。百川國際投資股份有限公司:160,359股。7.原任期(例xx/xx/xx ~ xx/xx/xx:102/06/17 ~ 105/06/168.新任生效日期:104/04/099.同任期監察人變動比率:不適用(全面改選)10.其他應敘明事項:無。

 

 

環瑞醫: 稅後虧損5.31億元

環瑞醫去年每股淨損4.12 挾雙利多今年營運先蹲後跳 鉅亨網記者張旭宏 台北2015-04-0111:41承業醫(4164-TW)投資的醫學影像診斷大廠環瑞醫(4198-TW)去年在研發增加下,導致營業費用大增,拖累營運,稅後虧損5.31億元,每股淨損4.12元,今年在baby X-ray原型機已開發完成,研發費用將會降低,加上瑞士技術移轉台灣,精簡費用,在雙利多挹注下,可望大幅降低營業費用,營運先蹲後跳。環瑞醫去年營收達6.24億元大幅成長82%,整體毛利率仍維持在18%以上,獲利下跌主要是2014年營業費用上升至5.37億元,台灣成立研發中心,加上原有瑞士研發費用發生所導致,但baby X-ray 原型機年初已開發完成,加上今年技術移轉台灣,精簡費用,營運成本可望大幅改善。 環瑞醫今年手推式Cruze設備出貨將會放量,另外中國客戶採購的X光機產品也在持續成長,加上埃及政府300萬美元訂單可望在第二季入帳,上半年月營收可望再創單月新高記錄,法人估計今年公司整體營收將有5成以上成長。環瑞醫目前營運資金充裕,去年上櫃募得8億元,至今仍尚未動支,加上原先所募得資金,將配合今年營收成長營運資金所用,短期無資金募集計劃。